3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Melanoma
8
Sarcoma
6
Breast Neoplasms
4
Triple Negative Breast Neoplasms
2
Neoplasm Metastasis
2
Carcinoma, Merkel Cell
2
Skin Neoplasms
1
Sarcoma, Kaposi
1
Pleural Effusion, Malignant
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Neurofibromatosis 1
1
Neurofibromatoses
1
Neurofibroma
1
Lymphoma, T-Cell, Cutaneous
1
Lung Neoplasms
1
Inflammatory Breast Neoplasms
1
Hemangiosarcoma
1
Carcinoma, Squamous Cell
1
Carcinoma, Ductal, Breast
1
Carcinoma, Ductal
1
Carcinoma, Basal Cell
1
Breast Carcinoma In Situ
1
Interventions
Cisplatin
55
Radiotherapy
33
Cetuximab
25
Paclitaxel
23
Carboplatin
23
Radiotherapy, Intensity-Modulated
21
pembrolizumab
19
Docetaxel
17
Fluorouracil
16
Nivolumab
14
Drug Therapy
11
Radiation
9
Erlotinib Hydrochloride
8
Blood Specimen Collection
8
durvalumab
7
Magnetic Resonance Spectroscopy
7
Surveys and Questionnaires
6
atezolizumab
5
Surgical Procedures, Operative
5
Radiosurgery
5
Esophagectomy
5
Chemoradiotherapy
5
olaparib
4
dacomitinib
4
Leucovorin
4
Cyclophosphamide
4
Capecitabine
4
Biopsy
4
Afatinib
4
fludarabine phosphate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Squamous Cell
×
talimogene laherparepvec
×
Clear all
NCT03458117
2022-03-18
20139157 T-VEC
University of Zurich
Phase 1
Completed
26 enrolled